Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: Patients' and doctors' views

European Journal of Dermatology

Volumn 21, Issue 6, 2011, Pages 976-984

  Loquai, Carmen ^a   Schmidtmann, Irene ^a   Beutel, Manfred ^a   Sunderkötter, Cord ^b   Grabbe, Stephan ^a   Schiller, Meinhard ^b   Nashan, Dorothée ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adjuvant treatment; Melanoma; Pegylated interferon; Quality of life

Indexed keywords

ALPHA2A INTERFERON; PEGINTERFERON ALPHA2B;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONSULTATION; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; LOW DRUG DOSE; MALE; MEDICAL RECORD; MELANOMA; OUTPATIENT CARE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84855982908     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1514     Document Type: Article

References (45)

1. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
2. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U; Eastern Cooperative Oncology Group. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant highdose interferon for melanoma. Clin Cancer Res 2004; 10: 1670-7.
3. Kirkwood JM, Ibrahim JG, Sondrak VK, et al. High- and low-dose interferon alpha-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444-58.
4. Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1,5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998; 351: 1905-10.
5. Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16: 1425-9.
6. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29: 241-52.
7. Eggermont AM, Suciu S, MacKie R, et al. EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366: 1189-96.
8. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990; 19: 390-9.
9. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferonalpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-67.
10. Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alfa-2b formulation. Cancer 2002; 95: 389-96.
11. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut 2003; 52: 1784-7.
12. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
13. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001: 358: 958-65.
14. Lindsay KL, Trepo C, Heintges T, et al.; Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
15. Bex A, Mallo H, Kerst M, Haanen J, Horenblas S, de Gast GC. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunol Immunother 2005; 54: 713-9.
16. Bukowsky R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 2002: 3841-9.
17. Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver RT, Tendler C; PEG-Intron CML Study Group. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukaemia: a phase III study. Leukemia 2004; 18: 309-15.
18. Eggermont AM, Suciu S, Santinami M, et al.; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008: 117-26.
19. Eigentler TK, Gutzmer R, Hauschild A, Vogt T, Linse R, Garbe C. Safety data on adjuvant treatment of cutaneous melanoma patients with interferon-alpha2b and pegylated interferon-alpha2b: An interim analysis of 285 patients treated in Germany. J Clin Oncol 2007; 25(Suppl): 8561.
20. Bottomley A, Coens C, Suciu S, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009; 27: 2916-23.
21. Dixon S, Walters SJ, Turner L, Hancock BW. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer 2006; 94: 492-8.
22. Cole B, Gelber R, Kirkwood J, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of Interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group Study. J Clin Oncol 1996; 14: 2666-73.
23. Rataj D, Krajewska-Kulak E, Jankowiak B, et al. Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients. Cancer Nurs 2005. 28: 172-8.
24. Task PC, Paterson AG, Esper P, Pau J, Redman B. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology 2004; 13: 526-36.
25. Beusterien KM, Ackerman SJ, Plante K, et al. The health-related quality-of-life impact of histamine dihydrochloride plus interleukin- 2 compared with interleukin-2 alone in patients with metastatic melanoma. Support Care Cancer 2003; 11: 304-12.
26. Coates A, Thomson D, McLeod GR, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Caner 1993; 29A: 1731-4.
27. Kilbridge KL, Cole BF, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 2002; 20: 1311-8.
28. Chiarion-Sileni V, Del Bianco P, De Salvo GL, et al.; Italian Melanoma Intergroup (IMI). Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer 2003; 39: 1577-85.
29. Kiebert GM, Jonas DL, Middleton MR. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 2003; 21: 821-9.
30. Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 2001; 37: 1345-51.
31. Schlesinger-Raab A, Schubert-Fritschle G, Hein R, et al. Quality of life in localised malignant melanoma. Ann Oncol 2010; 21: 2428-35.
32. Holterhues C, Cornish D, van de Poll-Franse LV, et al. Impact of melanoma on patients' lives among 562 survivors: a Dutch populationbased study. Arch Dermatol 2011; 147: 177-85.
33. Cornish D, Holterhues C, van de Poll-Franse LV, Coebergh JW, Nijsten T. A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol 2009; 20(Suppl. 6): vi51-8.
34. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferonalpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-67.
35. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalfs of the EORTC Quality of Life Group: The EORTC QLQ-C30 Scoring Manual (3rd Edition). Published by: European Organisation for Research and Treatment of Cancer, Brussels 2001.
36. Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastases. Ann Oncol 2008. 19: 1195- 201.
37. Rasenack J, Zeuzem S, Feinman V, et al. Peginterferon α-2a (40 kD) [Pegasys®] improves HR-QOL outcomes compared with unmodified interferon α-2a [Roferon®]-A]. Pharmacoeconomics 2003; 21:341-349.
38. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-3.
39. Ware JEJ, Snow KK, Kosinski M, Gandek B. SF-36 health survey; manual and interpretation guide. Boston: the health Intitute, New England Medical Center; 1993.
40. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa- 2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
41. Loquai C, Nashan D, Hensen P, et al. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas. Eur J Dermatol 2008; 18: 29-35.
42. Bael-Copel LM, Kornblith AB, Batel PC, Holland JC. Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. Eur J Cancer 1997; 1: 29-32.
43. Wilson KA, Dowling AJ, Abdolell M, Tannock IF. Perception of quality of life by patients, partners and treating physicians. Qual Life Res 2000; 9: 1041-52.
44. Pearcy R, Waldron D, O'Boyle C, MacDonagh R. Proxy assessment of quality of life in patients with prostate cancer: how accurate are partners and urologists?. J R Soc Med 2008; 101: 133-8.
45. Fallowfield L, Ratcliffe D, Jenkins V, Saul J. Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer 2001; 84: 1011-5.